Cariprazine in bipolar disorder: Clinical efficacy, tolerability, and place in therapy

Advances in Therapy

Volumn 30, Issue 2, 2013, Pages 102-113

  Citrome, Leslie ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Antipsychotic; Bipolar disorder; Cariprazine; Depression; Dosing; Efficacy; Mania; Manic mixed; Tolerability

Indexed keywords

ARIPIPRAZOLE; CARIPRAZINE; PLACEBO; DOPAMINE 3 RECEPTOR; PIPERAZINE DERIVATIVE; TRANQUILIZER;

AKATHISIA; BIPOLAR DISORDER; BIPOLAR MANIA; BLURRED VISION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYNDROME; HUMAN; INCIDENCE; INSOMNIA; LIMB PAIN; MIXED MANIA AND DEPRESSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW; TREMOR; VOMITING; YOUNG MANIA RATING SCALE; AGONISTS; TREATMENT OUTCOME; DRUG POTENTIATION;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D3; TREATMENT OUTCOME;

EID: 84891656753     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0004-9     Document Type: Review

References (37)

1. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123:175-89.
2. Ketter TA, Wang PW. Chapter 5: Overview of pharmacotherapy for bipolar disorders. In: Ketter TA. Handbook of Diagnosis and Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, Inc.; 2010:83-106.
3. American Psychiatric Association. New Research Abstracts, 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC.
4. American Psychiatric Association. New Research Abstracts, 162nd Annual Meeting of the American Psychiatric Association; May 16-21, 2009; San Francisco, CA.
5. American Psychiatric Association. New Research Abstracts, 163rd Annual Meeting of the American Psychiatric Association; May 22-26, 2010; New Orleans, LA.
6. American Psychiatric Association. New Research Abstracts, 164th Annual Meeting of the American Psychiatric Association; May 14-18, 2011; Honolulu, HI.
7. American Psychiatric Association. New Research Abstracts, 165th Annual Meeting of the American Psychiatric Association; May 5-9, 2012; Philadelphia, PA.
8. American Psychiatric Association. Syllabus and Proceedings Summary, 60th Institute on Psychiatric Services; October 2-5, 2008; Chicago, IL.
9. American Psychiatric Association. Syllabus and Proceedings Summary, 61st Institute on Psychiatric Services; October 8-11, 2009; New York, NY.
10. American Psychiatric Association. Syllabus and Proceedings Summary, 62nd Institute on Psychiatric Services; October 14-17, 2010; Boston, MA.
11. American Psychiatric Association. Syllabus and Proceedings Summary, 63rd Institute on Psychiatric Services; October 27-30, 2011; San Francisco, CA.
12. American Psychiatric Association. Syllabus and Proceedings Summary, 64th Institute on Psychiatric Services, New York City, New York, October 4-7, 2012.
13. National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 48th Annual NCDEU Meeting; May 27-30, 2008; Phoenix, AZ.
14. National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 49th Annual NCDEU Meeting; June 29- July 2, 2009; Hollywood, FL.
15. National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 50th Annual NCDEU Meeting; June 14- 17, 2010; Boca Raton, FL.
16. American Society of Clinical Psychopharmacology. Poster Abstracts. 51st Annual NCDEU Meeting; June 14-17, 2011; Boca Raton, FL.
17. American Society of Clinical Psychopharmacology. Poster Abstracts. 52nd Annual NCDEU Meeting; May 29-June 1, 2012; Phoenix, AZ.
18. American College of Neuropsychopharmacology. Program book. 47th Annual Meeting; December 7-11, 2008; Scottsdale, AZ.
19. American College of Neuropsychopharmacology. Program book. 48th Annual Meeting; December 6-10, 2009; Hollywood, FL.
20. American College of Neuropsychopharmacology. Program book. 49th Annual Meeting; December 5-9, 2010; Miami Beach, FL.
21. American College of Neuropsychopharmacology. Program book. 50th Annual Meeting; December 4-8, 2011; Waikoloa Beach, HI.
22. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30:114-26.
23. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2013;9:193-206.
24. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328-40.
25. Kapas M, Meszaros GP, Yu B, et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol. 2008;18:433.
26. Kirschner N, Gemesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008;40:128-9.
27. Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar disorder: a phase II trial. Poster presentation NR1-49, American Psychiatric Association 162nd Annual Meeting; May 16-21, 2009; San Francisco, CA.
28. Starace A, Bose A, Wang Q, et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trial. Poster presentation NR9-42, American Psychiatric Association 165th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
29. Forest Laboratories, Inc. and Gedeon Richter Plc anounce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder [press release]. Forest Laboratories, Inc.; 8 February 2012. Available at: http://news.frx.com/press- release/product-news/forest-laboratories-inc-and-gedeon-richter-plcannounce- positive-phase-ii. Accessed November 6 2012.
30. Forest Laboratories, Inc. and Gedeon Richter Plc announce results from a phase II study of cariprazine for the treatment of bipolar depression [press release]. Forest Laboratories, Inc.; 30 August 2010. Available at: http://news.frx.com/press-release/rd-news/forest-laboratories-inc-and-gedeon- richterplc-announce-results-phase-ii-stu-0. Accessed November 6 2012.
31. Safety, tolerability, and efficacy of cariprazine for patients with bipolar depression. Forest Laboratories, Inc. ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/ct2/show/NCT01396447. Accessed November 6 2012.
32. Safety and efficacy of RGH-188 (cariprazine) in bipolar depression. Forest Laboratories, Inc. ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/ct2/show/NCT00852202. Accessed November 6 2012.
33. Long-term safety and tolerability of cariprazine for bipolar I disorder. Forest Laboratories, Inc. ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/ct2/show/NCT01059539. Accessed November 6 2012.
34. Geodon (ziprasidone) [product information]. Pfizer, NY, USA; revised October 2012. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=584. Accessed January 11 2013.
35. Abilify (aripiprazole) [product information]. Otsuka Pharmaceutical Co., Tokyo, Japan; revised February 2012. Available at: http://www.abilify.com/pdf/ pi.aspx. Accessed November 12 2012.
36. Saphris (asenapine) [product information]. Merck & Co., NJ, USA; revised October 2012. Available at: http://www.merck.com/product/usa/pi- circulars/s/saphris/saphris-pi.pdf. Accessed January 11 2013.
37. Citrome L. A review of aripiprazole in thetreatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2:427-43.